摘要
一位新闻记者-机器人与机器学习的工作人员新闻编辑每日新闻-肿瘤学的新研究-癌症是一篇报道的主题。根据来自比利时鲁汶的新闻报道，NewsRx记者报道，研究表明，“晚期透明细胞肾细胞癌OMA(aRCC)患者的现实管理中的一个重要挑战是确定谁可能从免疫检查点阻断(ICB)中受益。在此，我们对ICB治疗背景下的aRCC进行了全面的多组学图谱。在真实世界的数据队列中进行发现分析，然后在独立的队列中进行验证。我们的新闻编辑从Leuve N大学（KU Leuven）的研究中获得了一句话，“我们交叉连接了超过1000名患者的体瘤转录组，并以单细胞和空间分辨率进行验证。”揭示了促炎性肿瘤相关巨噬细胞和（预）耗竭的CD8 T细胞之间的患者特异性串扰，其特征在于人类白细胞抗原库对肿瘤新抗原具有更高的偏好。交叉组学机器学习管道帮助获得了新的肿瘤转录足迹，有利于新抗原的人类白细胞抗原等位基因。这种机器学习特征与真实数据和独立临床队列中ICB治疗后的阳性结果相关。使用RENCA-肿瘤MO使用模型的实验，CD40激动结合PD1阻断增强了促炎肿瘤相关巨噬细胞和CD8 T细胞，从而相对于其他试验方案实现了最大的抗肿瘤功效。
Abstract
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Oncology - Carcinomas is the subject of a report. According to news reporting originating from Leuven, Belgium, by NewsRx correspondents, research stated, “An important challenge in the real-world management of patients with advanced clear-cell renal cell carcin oma (aRCC) is determining who might benefit from immune checkpoint blockade (ICB ). Here we performed a comprehensive multiomics mapping of aRCC in the context o f ICB treatment, involving discovery analyses in a real-world data cohort follow ed by validation in independent cohorts.” Our news editors obtained a quote from the research from the University of Leuve n (KU Leuven), “We cross-connected bulk-tumor transcriptomes across > 1,000 patients with validations at single-cell and spatial resolutions, revealin g a patient-specific crosstalk between proinflammatory tumor-associated macropha ges and (pre-)exhausted CD8 T cells that was distinguished by a human leukocyte antigen repertoire with higher preference for tumoral neoantigens. A cross-omics machine learning pipeline helped derive a new tumor transcriptomic footprint of neoantigen-favoring human leukocyte antigen alleles. This machine learning sign ature correlated with positive outcome following ICB treatment in both real-worl d data and independent clinical cohorts. In experiments using the RENCA-tumor mo use model, CD40 agonism combined with PD1 blockade potentiated both proinflammat ory tumor-associated macrophages and CD8 T cells, thereby achieving maximal anti tumor efficacy relative to other tested regimens.”
NETL
NSTL